AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$UTHR

ROTHBLATT MARTINE A sold $1.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 1,920 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $550.22 ($547.29–$554.70, $1.06M total) across 8 trades on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 1, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale reduces the CEO's stake and may be interpreted as a negative signal by investors.

02

Market read

A modest insider sell that could trigger short‑term price pressure but unlikely to affect long‑term outlook.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post‑market

Background

SEC Form 4 filing discloses insider transactions required by law.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Form 4 filing shows Chairperson & CEO sold $1.05M of shares via a 10b5‑1 plan, reducing holdings to 324,443 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $1M sale by the CEO is material for a mid‑cap biotech and often triggers short‑term selling.

Market effects

Sector

May raise concerns for the biotech sector about insider sentiment.

Regional

Limited to U.S. markets where UTHR trades.

Global

Minimal; impact confined to the company's stock.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company developing therapies for pulmonary arterial hypertension.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min